-
19m 8sPart 2 | Session 2 Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
13m 11sPart 2 | Session 3 Day 2 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
14m 10sPart 2 | Session 4 Day 1 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
13m 4sPart 3 | Session 1 VICTOR: Vericiguat in Heart Failure
-
12m 24sPart 3 | Session 2 DIGIT-HF: Cardiac Glycosides in HFrEF
-
12m 36sPart 3 | Session 3 BETAMI-DANBLOCK: Beta-blockers after MI
-
14m 3sPart 3 | Session 4 ESC 25 Guidelines Discussion: Management of Dyslipidaemias
-
14m 30sPart 3 | Session 5 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
-
27m 8s
-
4m 15sPart 4 | Session 1 TRISCEND II Trial: TTVR Outcomes by Baseline TR Severity
-
3m 52sPart 4 | Session 2 The VICTOR & VICTORIA Pooled Analysis
-
5m 10s
-
7m 42sPart 4 | Session 4 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism
-
7m 12s
-
6m 54sPart 4 | Session 6 STEEER-AF Cluster Randomised Trial by the ESC and EHRA
-
10m 5sPart 4 | Session 7 NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency
-
7m 43s
-
6m 35sPart 4 | Session 9 SWEDEPAD 1 and 2: Drug-Coated Devices in Peripheral Arterial Disease
-
5m 6sPart 4 | Session 10 Lifetime Benefits of Combination Therapy in HFpEF
-
3m 53sPart 4 | Session 11 REBOOT-CNIC: Beta-blockers After Infarction with LVEF Greater Than 40%
-
4m 31sPart 4 | Session 12 ODYSSEY-HCM: Mavacamten in Non-obstructive Hypertrophic Cardiomyopathy
-
6m 37sPart 4 | Session 13 Pooled MACE Data for Obicetrapib
-
8m 9sPart 4 | Session 14 STRIDE: Outcomes by Sex
-
4m 27sPart 4 | Session 15 The SEMA-VR CardioLink-15 Trial
-
7m 20sPart 4 | Session 16 The CARUSO Trial: Carotid Plaques Stabilisation and Regression with Evolocumab
-
3m 38sPart 4 | Session 17 EMORI-HCM: Electromagnetically Optimised Right Ventricular Pacing for oHCM
-
47m 54sPart 1 | Session 1 View from the Thoraxcenter: ESC 25 Late-breaking Science Wrap-Up
-
36m 33sPart 1 | Session 2 View from the Thoraxcenter: What's Hot at ESC 25?
ESC Congress 2025 – The fourth and final day of ESC Congress 2025 maintained momentum with transformative clinical data that will influence cardiovascular practice worldwide.
Leading interventional experts Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (King Fahd Armed Forces Hospital, SA) offer their expert commentary on the standout hot line trials and their clinical significance from day four.
Day 4 Highlights:
HELP-MI SWEDEHEART
TACSI
MHYH
NEWTON-CABG CardioLink 5
Watch the Day 3 ESC 25 wrap-up from Dr Alasnag and Dr Al-Shaibi here.
Recorded on-site at the ESC Congress 2025, Madrid.
Editors: Yazmin Sadik and Jordan Rance.
Dive into our coverage of ESC Congress 2025 for groundbreaking trial results and discussions with expert faculty.
- Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen.
- Watch our Wrap-Up series led by Dr Mirvat Alasnag summarising the key take-aways from each day of the congress.
- For clinical trial data from principal investigators, keep up with Dr Harriette Van Spall's Late-Breaker Discussion series.
- Our concise, accessible Expert Interviews will focus on the current data and it's impact on clinical practice.
- Don't miss the Highlights series to stay ahead of the curve in each field.
- In the Journal Discussions series, authors of ECR Journal explore their special focuses in depth.
More from this programme
Part 1
View from the Thoraxcenter: What's Hot at ESC 25?
Part 2
Daily Wrap Ups with Dr Mirvat Alasnag
Part 3
Hot-line Discussions with Dr Harriette Van Spall
Part 4
Expert Interviews
Part 5
Highlights
Faculty Biographies
Mirvat Alasnag
Director of Catheterization Laboratory
Dr. Mirvat Alasnag is a consultant interventional cardiologist based in Jeddah, Saudi Arabia. She is Director of the Catheterization Laboratory at King Fahad Armed Forces Hospital, where she has played a central role in the development of contemporary interventional cardiology services. Dr. Alasnag is recognised as the first female interventional cardiologist in the Gulf region and has been a prominent advocate for women in cardiology, representing female physicians on multiple national and international committees.
Academic History
Dr. Alasnag completed her training in Clinical Cardiology at Loma Linda University Medical Center in Loma Linda, California. She subsequently undertook advanced training in Interventional Cardiology at Harper University Hospital, Detroit Medical Center, in Detroit, Michigan. Her training combined high-volume clinical practice with exposure to complex coronary interventions, forming the foundation for her subsequent leadership…
Khaled Al-Shaibi
Director Cardiac Center
Dr Khaled Al-Shaibi is the Director at King Fahd Armed Forces Hospital. He earned his Doctor of Medicine degree from King Abdulaziz University in Jeddah, Saudi Arabia, in 1986.
Dr Al-Shaibi completed his residency in Internal Medicine at the University of Alabama at Birmingham (UAB) Medical Center from 1988 to 1991. Furthering his specialisation, Dr Al-Shaibi completed a Cardiology Fellowship at UAB Medical Center from 1991 to 1994, leading to his ABIM certification in Cardiovascular Disease in 1995. He then pursued advanced training through an Interventional Cardiology Fellowship at UAB Medical Center from 1994 to 1996, earning ABIM certification in Interventional Cardiology in 1997.
Dr Al-Shaibi's outstanding contributions to interventional cardiology in Saudi Arabia have been widely recognised. In 2016, he received the Lifetime Achievement Award from the Saudi Arabian Coronary Interventional Society. His dedication to the field of cardiology was further honoured by…
Comments